1. Waldenström J. Leber, Blutproteine und Nahrungseiweisse. Dtsch Gesellsch Verd Stoffw 1950; 15:113-119.
2. Leuschner U. Autoimmunkrankheiten der Leber und Overlap- Syndrome. Unimed Science, 2001.
3. Nishioka M, Morshed SA, McFarlane IG. Geographical variation in the frequency and characteristics of autoimmune liver diseases. In: Krawitt EL, Wiesner RH, Nishioka M, eds.
Autoimmune Liver diseases. Amsterdam: Elsevier, 1998:413-424.
4. Johnson PJ, McFarlane IG. Meeting report: International autoimmune hepatitis group.
Hepatology 1993; 18:998-1005.
5. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report:
review of criteria for diagnosis of autoimmune hepatitis. J. Hepatology 1999; 31:929-938.
6. Czaja A, Dos Santos, RM., Porto A et al. Immune phenotype of chronic liver disease. Dig Dis Sci 1998; 43:2149-55.
7. Czaja A. Natural History, clinical features and treatment of autoimmune hepatitis. Semin Liver Dis 1984; 4:1-12.
8. Czaja AJ. Autoimmune hepatitis: Evolving concepts and treatment strategies. Dig. Dis. Sci.
1995; 40:435-456.
9. Desmet VJ, Gerber M, Hoofnaagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19:1513-1520.
10. Manns MP, Strassburg CP. Autoimmune hepatitis: clinical challenges. Gastroenterology 2001;
120:1502-17.
11. Strassburg CP, Manns MP. Autoimmune hepatitis versus viral hepatitis C. Liver 1995; 15:225-232.
12. Strassburg CP, Obermayer-Straub P, Manns MP. Autoimmunity in hepatitis C and D virus infection. J. Viral. Hepat. 1996; 3:49-59.
13. Pawlotsky JM, Ben Yahia M, Andre C, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994; 19:841-848.
14. Lunel F, Cacoub P. Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection. J Hepatol 1999; 31 Suppl 1:210-6.
15. Autoren D. Klinisches Wörterbuch. Vol. Auflage 258: De Gruyter, 1997.
16. Nepom GT, Nepom BS. Prediction of susceptibility to rheumatoid arthritis by human leukocyte antigen genotyping. Rheum Dis Clin North Am 1992; 18:785-92.
17. Dittmar M, Kahaly GJ. Immunoregulatory and susceptibility genes in thyroid and polyglandular autoimmunity. Thyroid 2005; 15:239-50.
18. Badenhoop K, Walfish PG, Rau H, et al. Susceptibility and resistance alleles of human leukocyte antigen (HLA) DQA1 and HLA DQB1 are shared in endocrine autoimmune disease.
J Clin Endocrinol Metab 1995; 80:2112-7.
19. Yamamoto-Furusho JK. [Immunogenetics of chronic ulcerative colitis]. Rev Invest Clin 2003;
55:705-10.
20. Ahmad T, Marshall SE, Jewell D. Genetics of inflammatory bowel disease: the role of the HLA
56 Literaturverzeichnis
complex. World J Gastroenterol 2006; 12:3628-35.
21. Benovolenskaia LI, Iakovleva DB, Folomeeva OM. [The importance of HLA antigens for the prognosis of the course and effect of treatment in systemic lupus erythematosus]. Vutr Boles 1988; 27:48-52.
22. Lakomek HJ, Specker C, Kuntz BM, Goerz G. [Association of HLA-antigens with systemic lupus erythematodes and its symptoms (author's transl)]. Dtsch Med Wochenschr 1982;
107:766-70.
23. Gladman DD, Kung TN, Siannis F, Pellett F, Farewell VT, Lee P. HLA markers for susceptibility and expression in scleroderma. J Rheumatol 2005; 32:1481-7.
24. Autoren D. Psychrembel- Klinisches Wörterbuch. Vol. Auflage 258: De Gruyter, 1998.
25. Zamani M, Spaepen M, Sghar SS, et al. Linkage and association of HLA class II genes with vitiligo in a Dutch population. Br J Dermatol 2001; 145:90-4.
26. Carcassi C, Cottoni F, Floris L, et al. The HLA-DRB1*0101 allele is responsible for HLA susceptibility to lichen ruber planus. Eur J Immunogenet 1994; 21:425-9.
27. Czaja AJ, Manns MP. The validity and importance of subtypes in autoimmune hepatitis: a point of view. Am. J.Gastroenterol. 1995; 90:1206-1211.
28. Martini E, Abuaf N, Cavalli F, Durand V, Johanet C, Homberg JC. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 1988;
8:1662-6.
29. Lohr H, Treichel U, Poralla T, Manns M, Meyer zum Buschenfelde KH, Fleischer B. The human hepatic asialoglycoprotein receptor is a target antigen for liver-infiltrating T cells in autoimmune chronic active hepatitis and primary biliary cirrhosis. Hepatology 1990; 12:1314-20.
30. Treichel U, Gerken G, Rossol S, Rotthaue HW, Meyer zum Büschenfelde K-H, Portalla T.
Autoantibodies against the human asialoglycoprotein receptor: Effects of therapy in autoimmune and virus-induced chronic active hepatitis. J. Hepatology 1993; 19:55-63.
31. Strassburg CP, Alex B, Zindy F, et al. Identification of cyclin A as a molecular target of antinuclear antibodies (ANA) in hepatic and non-hepatic autoimmune diseases. J Hepatol 1996; 25:859-66.
32. Strassburg CP, Manns MP. Antinuclear antibody (ANA) patterns in hepatic and extrahepatic autoimmune disease. J Hepatol 1999; 31:751.
33. Czaja AJ, Ming C, Shirai M, Nishioka M. Frequency and significance of antibodies to histones in autoimmune hepatitis. J. Hepatol. 1995; 23:32-38.
34. Czaja AJ, Nishioka M, Morhed SA, Haciya T. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology 1994;
107:200-207.
35. Clifford BD, Donahue D, Smith S, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995; 231:613-619.
36. Lenzi M, Bellentani S, Saccoccio G, et al. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut 1999; 45:435-41.
37. Goldstein NS, Bayati N, Silverman AL, Gordon SC. Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis. Am J Clin Pathol 2000; 114:591-8.
57 Literaturverzeichnis
38. Czaja AJ, Morshed SA, Parveen S, Nishioka M. Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. Hepatology 1997;
26:567-72.
39. Whittingham S, Irwin J, Mackay IR, Smalley M. Smooth muscle autoantibody in "autoimmune"
hepatitis. Gastroenterology 1966; 51:499-505.
40. Toh BH. Smooth muscles autoantibodies and autoantigens. Clin. Exp. Immunol. 1979; 38:621-628.
41. Dighiero G, Lymberi P, Monot C, Abuaf N. Sera with high levels of anti-smooth muscle and anti-mitochondrial antibodies frequently bind to cytoskeleton proteins. Clin Exp Immunol 1990;
82:52-6.
42. Kurki P, Miettinen A, Linder E, Pikkarainen P, Vuoristo M, Salaspuro MP. Different types of smooth muscle antibodies in chronic active hepatitis and primary biliary cirrhosis: their diagnostic and prognostic significance. Gut 1980; 21:878-84.
43. Lidman K, Biberfeld G, Fagraeus A, et al. Anti-actin specificity of human smooth muscle antibodies in chronic active hepatitis. Clin Exp Immunol 1976; 24:266-72.
44. Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 1996; 24:1068-73.
45. Obermayer-Straub P, Strassburg CP, Manns MP. Autoimmune Hepatitis. J. Hepatol. 2000;
31:181-197.
46. Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J.
Hepatol. 1999; 30:394-401.
47. Obermayer-Straub P, Perheentupa J, Braun S, et al. Hepatic autoantigens in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Gastroenterology 2001;
121:668-77.
48. Clemente MG, Obermayer-Straub P, Meloni A, et al. Cytochrome P450 1A2 as the
hepatocellular autoantigen in autoimmune polyendocrine syndrome type 1. J. Hepatol 1995;
23:126.
49. Clemente MG, Meloni A, Obermayer-Straub P, Frau F, Manns MP, De Virgiliis S. Two cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1. Gastroenterology 1998; 114:324-8.
50. Gebre-Medhin G, Husebye ES, Gustafsson J, et al. Cytochrome P450IA2 and aromatic L-amino acid decarboxylase are hepatic autoantigens in autoimmune polyendocrine syndrome type I. FEBS Lett. 1997; 412:439-445.
51. Rizzetto M, Swana G, Doniach D. Microsomal antibodies in active chronic hepatitis and other disorders. Clin. Exp. Immunol. 1973; 15:331-344.
52. Homberg JC, Abuaf N, Bernard O, et al. Chronic active hepatitis associated with anti liver/kidney microsome type 1: a second type of "autoimmune" hepatitis. Hepatology 1987;
7:1333-1339.
53. Manns MP, Johnson EF, Griffin KJ, Tan EM, Sullivan KF. Major antigen of liver kidney microsomal antibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J. Clin.
Invest. 1989; 83:1066-1072.
54. Zanger UM, Hauri HP, Loeper J, Homberg JC, Meyer UA. Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type 2. Proc. Natl. Acad. Sci. USA 1988;
85:8256-8260.
58 Literaturverzeichnis
55. Guenguen M, Boniface O, Bernard O, Clerc F, Cartwright T, Alvarez F. Identification of the main epitope on human cytochrome P450IID6 recognized by anti-liver kidney microsome antibody. J. Autoimmun. 1991; 4:607-615.
56. Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J. Clin. Invest. 1991;
88:1370-1378.
57. Dalekos GN, Wedemeyer H, Obermayer-Straub P, et al. Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment. J Hepatol 1999; 30:366-75.
58. Durazzo M, Philipp T, Van Pelt FN, et al. Heterogeneity of liver-kidney microsomal
autoantibodies in chronic hepatitis C and D virus infection. Gastroenterology 1995; 108:455-62.
59. Zimmerman HJ, Lewis JH, Ishak KG, Maddrey W. Ticrynafen-associated hepatic injury:
Analysis of 340 cases. Hepatology 1984; 4:315-323.
60. Van Pelt F, Straub P, Manns M. Molecular basis of drug-induced immunological liver injury.
Semin. Liv. Dis. 1995; 15:283-300.
61. Beaune P, Dansette PM, Mansuy D, et al. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc. Natl. Acad. Sci. USA 1987; 84:551-555.
62. Jean P, Lopez-Garcia P, Dansette P, Mansuy D, Goldstein JL. Oxidation of tienilic acid by human yeast-expressed cytochromes P-450 2C8, 2C9, 2C18 and 2C19. Evidence that this drug is a mechanism-based inhibitor specific for cytochrome P-450 2C9. Eur. J. Biochem.
1996; 241:797-804.
63. Lecoeur S, Andre C, Beaune PH. Tienilic acidinduced autoimmune hepatitis: antiliver and -kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Mol. Pharmacol. 1996; 50:326-333.
64. Crivelli O, Lavarini C, Chiaberge E, et al. Microsomal autoantibodies in chronic infection with HBsAg associated delta (delta) agent. Clin. Exp. Immunol. 1983; 54:232-238.
65. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000; 40:581-616.
66. Lenzi M, Manotti P, Muratori L, et al. Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection. Gut 1995; 36:749-754.
67. Abuaf N, Johanet C, Chretien P, et al. Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology 1992; 16:892-8.
68. Han S, Tredger M, Gregorio GV, Mieli-Vergani G, Vergani D. Anti-liver cytosolic antigen type 1 (LC1) antibodies in childhood autoimmune liver disease. Hepatology 1995; 21: 58-62.
69. Lapierre P, Hajoui O, Homberg J-C, Alvarez F. Fomiminotransferase cyclodeaminase is an organ specific autoantigen recognized by sera of patients with autoimmune hepatitis.
Gastroenterology 1999; 116:643-649.
70. Muratori L, Cataleta M, Muratori P, Lenzi M, Bianchi FB. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut 1998; 42:721-6.
71. Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Buschenfelde KH. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987; 1:292-4.
59 Literaturverzeichnis
72. Stechemesser E, Klein R, Berg PA. Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology 1993; 18:1-9.
73. Wächter B, Kyriasoulis A, Lohse AW, Gerken G, Meyer zum Büschenfelde KH, Manns M.
Characterization of liver cytokeratin as a major antigen of anti-SLA antibodies. J. Hepatol.
1990; 11:232-239.
74. Wies I, Brunner S, Henninger J, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis [see comments]. Lancet 2000; 355:1510-5.
75. Wesierska-Gaedek J, Frimm R, Hitchman E, Penner E. Members of the glutathione S-transferase gene family are antigens in autoimmune hepatitis. Gastroenterology 1998;
1998:329-335.
76. Volkmann M, Martin L, Baurle A, et al. Soluble liver antigen: isolation of a 35-kd recombinant protein (SLA-p35) specifically recognizing sera from patients with autoimmune hepatitis.
Hepatology 2001; 33:591-6.
77. Vitozzi S, Lapierre P, Djilali-Saiah I, Marceau G, Beland K, Alvarez F. Anti-soluble liver antigen (SLA) antibodies in chronic HCV infection. Autoimmunity 2004; 37:217-22.
78. Manns M. Cytoplasmatic autoantigens in autoimmune hepatitis: Molecular analysis and clinical relevance. Semin Liver Dis 1991; 11:205-14.
79. Gelpi C SE, Rodriguez-Sanchez JL. Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion. Proc Natl Acad Sci U S A 1992;
89:9739-43.
80. Treichel U, Poralla T, Hess G, Manns M, Meyer zum Buschenfelde KH. Autoantibodies to human asialoglycoprotein receptor in autoimmune-type chronic hepatitis. Hepatology 1990;
11:606-12.
81. Portalla T, treichel U, Löhr H, Fleischer B. The asialoglycoprotein receptor as target structure in autoimmune liver diseases. Semin. Liver Dis. 1991; 11:215-222.
82. McFarlane IG, Hegarty JE, McSorley CG, McFarlane BM, Williams R. Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis. Lancet 1984; 2:954-6.
83. Czaja AJ, Pfeifer KD, Decker RH, Vallari AS. Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. Dig. Dis. Sci. 1996; 41:1733-1740.
84. Mulder AHL, Horst G, Haagsma EB, Limburg PC, Kleibeuker JH, Kallenberg GM. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases.
Hepatology 1993; 17:411-417.
85. Targan SR, Landers C, Vidrich A, Czaja AJ. High titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology 1995; 108:1159-1166.
86. Van der Woude FR, N. Lobatto, S. et al. Autoantibodies against neutrophiles and monocytes tool for diagnosis and marker of disease activity in Wegener´s granulomatosis. Lancet 1985;
i:425-9.
87. Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for
myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N. Engl. J. Med. 1988; 318:1651-1657.
88. Dalekos GM, MN. Goussia, AC. et al. Soluble interleukin-2 receptors , antineutrophil
cytoplasmatic antibodies and other autoantibodies in patients with ulcerative colitis. Gut 1993;
34:658-64.
60 Literaturverzeichnis
89. Pokorny CN, ID. McCaughan, GW. et al. Antineutrophil-cytoplasmatic autoantibodies: a prognostic indicator n primary sclerosing cholangitis in patients with systemc vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. J Gastroenterol Hepatol 1994; 9:40-4.
90. Kanzler S, Weidemann C, Gerken G, et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol 1999; 31:635-40.
91. Ballot E. HJ, Johanet C. Antibodies to soluble liver antigen: an additional marker in type 1 auto-immune hepatitis. J Hepato 2000; 33:208-15.
92. Manns M. Antibodies to soluble liver antigen: specific marker of autoimmune hepatitis. J Hepatol 2000; 33:326-8.
93. Gregorio GV, Portman B, Reid F, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997; 25:541-547.
94. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease.
Hepatology 1998; 28:360-5.
95. Czaja A. Variant forms of autoimmune hepatitis. Curr Gastroenterol Rep 1999; 1:63-70.
96. Donaldson P. Genetics of liver disease: immunogenetics and disease pathogenesis. Gut 2004;
53:599-608.
97. Donaldson P. Genetics in autoimmune hepatitis. Sem Liver Dis 2002; 4:353-363.
98. Mackay IR, Morris PJ. Association of autoimmune chronic hepatitis with HLA-A1-B8. Lancet 1972; 2:793-795.
99. Strettel MDJ, Donaldson PT, Thomson LJ, et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997; 112:2028-2035.
100. Czaja AJ, Strettell M, Thomson LJ, et al. Associations between alleles of the major
histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997; 25:317-323.
101. Strettell MD, Thomson LJ, Donaldson PT, Bunce M, O'Neill CM, Williams RW. HLA-C genes and susceptibility to type 1 autoimmune hepatitis. Hepatology 1997; 26:1023-1026.
102. Donaldson P, Doherty D, Underhill J, Williams R. The molecular genetics of autoimmune liver disease. Hepatology 1994; 20:225-229.
103. Seki T, Ota M, Furuta S, et al. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology 1992; 103:1041-7.
104. Vazquez-Garcia MN, Alaez C, Olivo A, et al. MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. J. Hepatol. 1998; 28:985-990.
105. Pando M, Larriba J, Fernandez GC, et al. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 1999;
30:1374-80.
106. Ota M, Seki T, Kiyoshawa K, et al. A possible association between basic amino acids of position 13 of DRB1 chains and autoimmune hepatitis. Immunogenetics 1992; 36:40-55.
107. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993; 105:1502-1507.
108. Donaldson PT, Doherty DG, Hayllar KM, Mc Farlane IG, Johnson PJ, Williams R.
Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR 4 and A1-B8-DR-3 are independent risk factors. Hepatology 1991; 13:701-706.
61 Literaturverzeichnis
109. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology 1993; 18:816-822.
110. Czaja AJ, Doherty DG, Donaldson PT. Genetic bases of autoimmune hepatitis. Dig Dis Sci 2002; 47:2139-50.
111. Cookson S, Constantini PK, Clare M, et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology 1999; 30:851-856.
112. Czaja AJ, Cookson S, Constantini PK, Clare M, Underhill JA, Donaldson PT. Cytokine
polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology 1999; 117:645-652.
113. Agarwal K, Jones DE, Daly AK, et al. CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J Hepatol 2000; 32:538-41.
114. Vogel A, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 2002; 35:126-131.
115. Kirk AP, Jain S, Pocock S, Thomas HC, Sherlock S. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980; 21:7893.
116. Czaja A. Treatment of autoimmune hepatitis. Sem Liver Dis 2002; 22:number 4:365-377.
117. Strassburg CM, MP. Definition, Diagnostik und Therapie der AIH. Der Kassenarzt 2000; 5:31-35.
118. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004; 40:646-52.
119. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996; 110:848-857.
120. Schvarcz R, Glaumann H, Weiland O. Survival and histological resolution of fibrosis in patients with autoimmune chronic active hepatitis. J Hepatol 1993; 18:15-23.
121. Schramm C, Kanzler S, zum Buschenfelde KH, Galle PR, Lohse AW. Autoimmune hepatitis in the elderly. Am J Gastroenterol 2001; 96:1587-91.
122. Newton JL, Burt AD, Park JB, Mathew J, Bassendine MF, James OF. Autoimmune hepatitis in older patients. Age Ageing 1997; 26:441-4.
123. Samuel D, Figueiro J, Bismuth H. Liver transplantation: Indications and Patient Selection. In:
O'Grady J, Lake JR, Howdle PD, eds. Comprehensive Clinical Hepatology. London: Mosby, 2000:34.1-34.17.
124. Vogel A, Heinrich E, Bahr MJ, et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant 2004; 18:62-9.
125. Ishak KB, A. Bianchi, L. et al. Histological staging and grading of chronic hepatitis. J Hepatol 1995; 22:696-699.
126. Payami H, Khan MH, Grennan DM, Sanders PA, Dyer PA, Thomson G. Analysis of genetic interrelationship among HLA-associated diseases. Am J Hum Genet 1987; 41:331-49.
127. Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002; 35:658-64.
128. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol 2002; 97:413-9.
62 Literaturverzeichnis
129. Doherty DG, Donaldson PT, Underhill JA, et al. Allelic sequence variation in the HLA class II genes and proteins on patients with autoimmune hepatitis. Hepatology 1994; 19:609-615.
130. Opeltz G, Vogten AJ, Summerskill WH, Schalm SW, Terasaki PI. HLA-determinants in chronic active liver disease: Possible relation of HLA-DRw3 to prognosis. Tissue Antigens 1977; 9:36-40.
131. Mackay IR, Tait BD. HLA association with autoimmune type chronic active hepatitis:
identification of B8-DRw3 haplotype by family studies. Gastroenterology 1980; 79:95-98.
132. Czaja AJ, Kruger M, santrach PJ, Breanndan Moore S, Manns MP. Genetic distinctions between types 1 and 2 autoimmune hepatitis. Am. J. Gastroenterol. 1997; 92:2197-2200.
133. Sanchez-Urdazpal L, Czaja AJ, Van Holk B. Prognostic features and role of liver
transplantation in severe corticoid-treated autoimmune chronic active hepatitis. Hepatology 1991; 15:215-221.
134. Czaja AJ. Drug therapy in the management of type 1 autoimmune hepatitis. Drugs 1999;
57:49-68.
135. Czaja AC, HA. Santrach, PJ. et al. Genetic predispositions for the immunologicalfeatures of chronic active autoimmune hepatitis. Hepatology 1993; 18:816-22.
136. Czaja AD, PT. Gender Effects and Synergisms With Histocompatibility Leukocyte Antigen in Type 1 Autoimmune Hepatitis. Am J Gastroenterol 2002; 97:2051-57.
137. Johnson PJ, McFarlane IG, Eddleston ALWF. The natural course and heterogeneity of autoimmune-type chronic active hepatitis. Semin. Liver. Dis. 1991; 11:187-196.
138. Czaja AJ, Donaldson PT. Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am J Gastroenterol 2002; 97:2051-7.
139. Tong MH, J. Blatt, LM. Demographics, treatment and a predictive model of survival in a population of chronic autoimmune hepatitis patients. Hepatology 1998; 28:549 A (abstract).
140. Heneghan MK, Y. McDougall, NI. et al. Characteristics and outcome of a large male cohort with autoimmune hepatitis: Male sex as a favorable prognostic indicator: Treatment response and outcome. Gastroenterology 2000:A1009 (abstract).
141. Granito A, Muratori L, Pappas G, et al. Clinical features of type 1 autoimmune hepatitis in elderly Italian patients. Aliment Pharmacol Ther 2005; 21:1273-7.
63 Anhang
7. APPENDIX
7.1. Abbildungsverzeichnis
ABBILDUNG 1:AIH-SCORE NACH ALVAREZ ET AL... 7
ABBILDUNG 2:HLA-KLASSE-I-MOLEKÜL... 17
ABBILDUNG 3:ISHAK-SCORE... 23
ABBILDUNG 4:PCR-CYCLING PARAMETER... 25
ABBILDUNG 5:UNTERSUCHTE HLA-ALLELE MIT ANGABE DER BASENPAARE. ... 27
ABBILDUNG 6:DARSTELLUNG DER PCRAMPLIFIKATION DER HLA-ALLELE. ... 27
ABBILDUNG 7:ÜBERSICHT AIH-SUBTYPEN... 28
7.2. Tabellenverzeichnis TABELLE 1:ALTER,ED SOWIE AIH-DAUER DER EINZELNEN AIH-SUBTYPEN... 29
TABELLE 2:DARSTELLUNG DER MEDIKAMENTÖSEN THERAPIE DER AIH-PATIENTEN... 30
TABELLE 3:LABORPARAMETER... 30
TABELLE 4:HLA-ALLELE DER AIH-PATIENTEN VS KONTROLLGRUPPE... 32
TABELLE 5:HLA-ALLELE VS ALTER... 33
TABELLE 6:ANTIKÖRPERVERTEILUNG... 34
TABELLE 7:ANTI-SLA/LP VS HLA-ALLELE... 35
TABELLE 8:HLA-ALLELE VS GESCHLECHT... 36
TABELLE 9:VERLAUF... 37
TABELLE 10:HISTOLOGIE... 38
TABELLE 11:LTX ... 38
TABELLE 12:LTX VS HLA-ALLELE... 39
TABELLE 13:EXTRAHEPATISCHE MANIFESTATIONEN... 40
TABELLE 14:HLA-ALLELE VS EXTRAHEPATISCHE AUTOIMMUNERKRANKUNGEN... 41
TABELLE 15.1:DATENÜBERSICHT SUBTYPEN 1 ... 42
TABELLE 15.2:DATENÜBERSICHT SUBTYPEN 2 ... 43
TABELLE 16.1:DATENÜBERSICHT GESCHLECHT 1... 43
TABELLE 16.2:DATENÜBERSICHT GESCHLECHT 2... 44
64 Anhang
7.3. Abkürzungsverzeichnis
AIH Autoimmunhepatitis
ALT/ GPT Alanin- Aminotransferase entspricht Glutamat- Pyruvat- Transaminase
AMA Antimitochondriale Antikörper
ANA Antinukleäre Antikörper
ANCA Anti-Neutrophile Cytoplasmatische Antikörper Anti- LC- 1 Antikörper gegen Leberzytosol
Anti- SLA/ LP Antikörper gegen lösliches Leberantigen/ Leber- Pankreas Antigen (Soluble liver-/ liver pancreas antibodies)
Anti- TG Threoglobulin- Antikörper
Anti- TPO Thyreoid- Peroxidase Antikörper
AP Alkalische Phosphatase
APECED Autoimmune Polyendokrinopathie- Candidiasis- Ektodermale Dystrophie
APS- 1 Autoimmun- Polyglanduläres Syndrom
ASGPR Asiaglykoproteinrezeptor
AST/ GOT Aspartat- Aminotransferase entspricht Glutamat- Oxalacetat- Transaminase
C2 Komplementfaktor 2
CED Chronisch entzündliche Darmerkrankung
CMV Cytomegalievirus
CREST- Syndrom Syndrom aus Calcinosis cutis, Raynaud- Syndrom, Ösophagusbeteiligung, Sklerodermie und Teleangiektasien
CTLA- 4 Zytotoxisches- Lymphozytenantigen 4
CU Colitis ulcerosa
CYP Cytochrom
DNA Desoxyribonukleinsäure
EBV Epstein- Barr- Virus
ED Erstdiagnose
EDTA Ethylendiamintetraessigsäure
ELISA Enzyme linked immunosorbent assay
ELTR Europäische Lebertransplantationsregister
ERCP Endoskopisch retrograde- Cholangio- Pankreatiko- Graphie
FK 506 Tacrolimus
FMS Fibromyalgie- Syndrom
FTCD Formiminotransferase- Cyclodeaminase
GGT Gammaglutamyltransferase
HA/ B/ C- V Hepatitis A/ B/ C- Virus
HLA Humanes Leukozytenantigen
IAIHG Internationale Autoimmunhepatitis Gruppe
65 Anhang
ITP Idiopathische Thrombozytopenische Purpura
LKM Leber- Niere- Mikrosomale- Antikörper
LTX Lebertransplantation
MC Morbus Crohn
MHC Haupthistokompatibilitätskomplex
MMF Mycophenolat Mofetil
OLT Orthotope Lebertransplantation
PBC Primär- Biliäre- Zirrhose
PCR Polymerasekettenreaktion
PSC Primär- Sklerosierende- Cholangitis
SLE Systemischer Lupus erythematodes
SMA Antikörper gegen glatte Muskelzellen (Smooth- muscle- antibodiese)
SNP Single nucleotide Polymorphism
TBE Tris- Borat EDTA- Puffer
TNF Tumornekrosefaktor
TRAK TSH- Rezeptor- Antikörper
TZR T- Zell- Rezeptor
UGT1A Uridin 5` Glucuronosyltransferase
VDR Vitamin- D- Rezeptor
WHO World- Health- Organisation
66 Anhang
7.4. Patientenaufklärung und Einwilligung
EINWILLIGUNG ZUR BLUTABNAHME FÜR EINE WISSENSCHAFTLICHE UNTERSUCHUNG
AUTOIMMUNHEPATITIS (AIH, Leberentzündung autoimmuner Genese) ist eine chronische Erkrankung, deren Ursache bis zum heutigen Tage unklar ist. Die Diagnose wird aus einer Vielzahl histologischer, anamnestischer
AUTOIMMUNHEPATITIS (AIH, Leberentzündung autoimmuner Genese) ist eine chronische Erkrankung, deren Ursache bis zum heutigen Tage unklar ist. Die Diagnose wird aus einer Vielzahl histologischer, anamnestischer